If your gastroenterologist has prescribed Omvoh for Crohn's disease and you have a Blue Cross Blue Shield plan, the honest answer to whether it is covered is that it depends on your specific plan. Blue Cross Blue Shield is not a single insurer. It is a federation of more than 30 independent, locally operated companies, each running its own formulary, prior authorization rules, and step therapy requirements. Omvoh, the brand name for mirikizumab, only received FDA approval for moderately to severely active Crohn's disease in January 2025, which makes it one of the newest options in the category and one that most plans have only recently begun to address in their published policies. This article explains why coverage varies, what your Blue plan will likely require, and how to find the rules that actually apply to you.
Why Coverage Depends on Your Specific Blue Plan
There is no national Blue Cross Blue Shield policy on Omvoh. Anthem, Blue Cross Blue Shield of Michigan, Independence Blue Cross, and dozens of other Blue licensees each set their own coverage criteria. Your benefits are also shaped by whether your plan is commercial, an Affordable Care Act marketplace plan, Medicare Advantage, or Medicaid, and by which pharmacy benefit manager administers your drug benefit, often CarelonRx or Prime Therapeutics. Because Omvoh is a biologic given partly by intravenous infusion, it may be processed under your medical benefit rather than your pharmacy benefit, which changes how prior authorization is handled. A drug that is covered with one set of conditions in one state may sit on a different tier, or require different documentation, under a Blue plan in another state. This is why a friend's approval in another state tells you almost nothing about your own.
What Omvoh Is and Where It Fits in Treatment
Omvoh is a humanized monoclonal antibody that selectively binds the p19 subunit of interleukin-23, an inflammatory signaling protein involved in Crohn's disease. For Crohn's, the label calls for 900 mg given intravenously at weeks 0, 4, and 8 for induction, followed by 300 mg subcutaneously at week 12 and every four weeks after that for maintenance. Its approval was supported by the phase 3 VIVID-1 trial published in The Lancet, in which 45.4 percent of mirikizumab patients reached clinical remission at week 52 versus 19.6 percent on placebo. The AGA living guideline for moderate-to-severe Crohn's disease lists mirikizumab among its recommended advanced therapies. Because it is so new, plans frequently position it behind older, less expensive biologics.
The Step Therapy and Prior Authorization Hurdles
Almost every Blue plan requires prior authorization for Omvoh, and most will not approve it as a first-line biologic. Plans typically gate newer agents behind documented failure of preferred products. As a concrete example, the Blue Cross Blue Shield of Michigan medical policy for Omvoh requires that conventional therapy, such as corticosteroids or an immunomodulator like azathioprine, has been ineffective, not tolerated, or contraindicated, and separately requires trial and failure of, or intolerance to, the preferred drugs on its utilization management list before Omvoh is approved. Other Blue plans publish similar criteria, though the specific preferred agents differ. Worth noting, the AGA guideline now suggests upfront use of advanced therapy over a slower step-up approach, which can create tension between clinical guidance and an insurer's step therapy rules. Where they conflict, your prescriber may need to argue medical necessity.
How to Find Your Plan's Actual Rules
Do not rely on general information for a decision this specific. Three documents will tell you what your plan requires.
Your plan's formulary or drug list, which shows whether Omvoh is covered and on what tier
Your plan's medical or pharmacy coverage policy for mirikizumab, which lists the exact prior authorization and step therapy criteria
Your Summary of Benefits and Coverage, which explains your specialty drug cost sharing
You can usually find these by logging into your member portal, searching the public provider policy library on your Blue plan's website, or calling the member services number on your insurance card. Ask specifically whether Omvoh is processed under the medical or pharmacy benefit, since that determines who submits the authorization. Because plan documents change at least annually, confirm you are reading the version in effect for your current benefit year.
Building a Strong Case and Appealing a Denial
If your plan requires step therapy, the strength of your approval depends on documentation. Your gastroenterologist's prior authorization request should clearly establish the diagnosis, disease severity, and a complete history of prior therapies, including each preferred agent tried, the dates, and why it was stopped, whether for inadequate response, loss of response, or intolerance. Because Omvoh is a later-line agent for most plans, a denial often turns on missing or vague records of earlier treatments rather than on the drug itself. If you are denied, you have the right to appeal, and many denials are overturned when the medical necessity record is complete. Request the specific reason in writing, ask your prescriber to address each cited criterion, and submit a formal appeal within your plan's deadline. A peer-to-peer review between your gastroenterologist and the plan's medical reviewer can also resolve borderline cases.
The Bottom Line on Blue Cross and Omvoh
Whether Blue Cross Blue Shield covers Omvoh for Crohn's disease has no universal answer because there is no universal Blue plan. Omvoh is FDA approved for Crohn's and is recognized in current treatment guidelines, so the question is rarely whether it can be covered at all and almost always under what conditions your particular plan will pay for it. For most members that means prior authorization and documented failure of one or more preferred biologics before approval. The most reliable path is to read your own plan's formulary and mirikizumab coverage policy, confirm whether the drug falls under your medical or pharmacy benefit, and work with your gastroenterologist to assemble a thorough treatment history before the request is ever submitted. That preparation is what turns a likely denial into an approval.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.